Bibliography
- Maquet P. Sleep function(s) and cerebral metabolism. Behav Brain Res 1995;69(1-2):75-83
- Maquet P. The role of sleep in learning and memory. Science 2001;294(5544):1048-52
- Aserinsky E, Kleitman N. Regularly occurring periods of eye motility, and concomitant phenomena, during sleep. Science 1953;118(3062):273-4
- Rechtschaffen A, Kales A. A manusal of standardized, terminology, techniques and scoring system of sleep stages in human subjects. Brain information service/Brain research institute. University of California; Los Angeles: 1968
- Iber CA-I S, Chesson A, Quan SF. The aasm manual for the scoring of sleep and associated events: rules, terminology and technical specifications. American Academy of Sleep Medicine; Westchester: 2007
- Beersma DG. Models of human sleep regulation. Sleep Med Rev 1998;2(1):31-43
- Espana RA, Scammell TE. Sleep neurobiology for the clinician. Sleep 2004;27(4):811-20
- Saper CB, Lu J, Chou TC, Gooley J. The hypothalamic integrator for circadian rhythms. Trends Neurosci 2005;28(3):152-7
- Stenberg D. Neuroanatomy and neurochemistry of sleep. CMLS 2007;64(10):1187-204
- Jones BE. From waking to sleeping: neuronal and chemical substrates. Trends Pharmacol Sci 2005;26(11):578-86
- Deurveilher S, Burns J, Semba K. Indirect projections from the suprachiasmatic nucleus to the ventrolateral preoptic nucleus: a dual tract-tracing study in rat. Eur J Neurosci 2002;16(7):1195-213
- Wesensten NJ, Balkin TJ, Reichardt RM, Daytime sleep and performance following a zolpidem and melatonin cocktail. Sleep 2005;28(1):93-103
- Wyatt JK, Dijk DJ, Ritz-de Cecco A, Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 2006;29(5):609-18
- Zisapel N. Sleep and sleep disturbances: biological basis and clinical implications. Cell Mol Life Sci 2007;64(10):1174-86
- American Psychiatric Association. Primary insomnia. In: Diagnostic and statistical manual of mental disorders. 4th edition. DSM-IV Available from: http://psychiatryonline.org/ [Accessed 2012]
- World Health Organization -Who Nonorganic insomnia. In: International classification of diseases. 10th edition. ICD-10 Available from: http://apps.who.int/classifications/icd10/browse/2010/en [Accessed 2012]
- Roth T, Zammit G, Lankford A, Nonrestorative sleep as a distinct component of insomnia. Sleep 2010;33(4):449-58
- Edinger JD BM, BootZin RR, Doghramji K, Derivation of research diagnostic criteria for insomnia: report of an american academy of sleep medicine work group. Sleep 2004;27(8):1567-96
- Littner M, Hirshkowitz M, Kramer M, Practice parameters for using polysomnography to evaluate insomnia: an update. Sleep 2003;26(6):754-76
- Dement W, Miles LE, Carskadon MA. “White paper” on sleep and aging. J Am Geriatr Soc 1982;30(1):25-30
- Leger D PB, Neubauer D, Uchiyama M. An international survey of sleeping problems in the general population. Curr Med Res Opin 2008;24(1):307-17
- Rediehs MH RJ, Creason NS. Sleep in old age: focus on gender differences. Sleep 1990;13(5):410-24
- Fullerton DS. The economic impact of insomnia in managed care: a clearer picture emerges. Am J Manag Care 2006;12(8 Suppl):S246-52
- Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6(2):97-111
- Drake CL, Roehrs T, Roth T. Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety 2003;18:163-76
- Monane M. Insomnia in the elderly. J Clin Psychiatry 1992;53(Suppl):23-8
- Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the unites states: results of the 1991 national sleep foundation survey. Sleep 1999;22:S354-8
- Roth T, Roehrs T. Insomnia: epidemiology, characteristics, and consequences. Clin Cornerstone Chronic Insomnia 2003;5(3):5-15
- Bliwise DL KA, Harris RB, Haskell WL. Prevalence of self-reported poor sleep in a healthy population aged 50-65. Soc Sci Med 1992;34(1):49-55
- Morgan K Healey DW, Healey PJ. Factors influencing persistent subjective insomnia in old age: a follow-up study of good and poor sleepers aged 65 to 74. Age Ageing 1989;18(2):117-22
- Ohayon M. Prevalence of dsm-iv diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatry Res 1997;31(3):333-46
- Ancoli-Israel S, Roth T. Characteristics of insomnia in the united states: results of the 1991 national sleep foundation survey.I. Sleep 1999;22:S347-53
- Ohayon M, Lemoine P. Daytime consequences of insomnia complaints in the french general population. Encephale 2004;30(3):222-7
- Ohayon M, Zulley J. Correlates of global sleep dissatisfaction in the german population. Sleep 2001;24(7):780-7
- Morgan K DH, Ebrahim S, Arie T, Fentem PH. Characteristics of subjective insomnia in the elderly living at home. Age Ageing 1988;17(1):1-7
- Zeitlhofer J, Schmeiser-Rieder A, Tribl G, Sleep and quality of life in the austrian population. Acta Neurol Scand 2000;102:249-57
- Ustun T, Privett M, Lecrubier Y, Form, frequency and burden of sleep problems in general health care: a report from the who collaborative study on psychological problems in general health care. Eur Psyshiatry 1996;11(1):1087-96
- Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262(11):1479-84
- Pearson NJ JL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: analysis of the 2002 national health interview survey data. Arch Intern Med 2006;166(16):1775-82
- Taylor DJ, Mallory LJ, Lichstein KL, Comorbidity of chronic insomnia with medical problems. Sleep 2007;30(2):213-18
- Roth T. Comorbid insomnia: current directions and future challenges. Am J Manag Care 2009;15(Suppl):S6-S13
- Hauri PJ. Cognitive deficits in insomnia patients. Acta Neurol Belg 1997;97(2):113-17
- Crenshaw C. Slow-wave sleep and waking cognitive performance among older adults with and without insomnia complaints. Physiol Behav 1999;66(3):485-92
- Hoevenaar-Blom M, Spijkerman A, Kromhout D, Sleep duration and sleep quality in relation to 12-year cardiovascular disease incidence the morgen study. Sleep 2011;34(11):1587-492
- Bansil P, Kuklina E, Merritt R, Yoon P. Associations between sleep disorders, sleep duration, quality of sleep, and hypertension: results from the national health and nutrition examination survey, 2005 to 2008. J Clin Hypertens (Greenwich) 2011;13(10):739-43
- SZuba MP Kloss JD, Dinges DF. Insomnia, principles and management. Cambridge University Press; Cambridge: 2003
- Wilson SJ, Nutt DJ, Alford C, British association for psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010;24(11):1577-601
- Mendelson WB. Effects of flurazepam and zolpidem on the perception of sleep in normal volunteers. Sleep 1995;18:88-91
- Rudolph U, Antkowiak B. Molecular and neuronal substrates for general anaesthetics. Nat Rev Neurosci 2004;5(9):709-20
- Glass J, Lanctot KL, Herrmann N, Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169-76
- Szabadi E. Drugs for sleep disorders: mechanisms and therapeutic prospects. Br J Clin Pharmacol 2006;61(6):761-6
- Lader M. Benzodiazepines revisited–will we ever learn? Addiction 2011;106(12):2086-109
- Berggren L, Eriksson I, Mollenholt P, Sunzel M. Changes in respiratory pattern after repeated doses of diazepam and midazolam in healthy subjects. Acta Anaesthesiol Scand 1987;31(8):667-72
- Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004;18(5):297-328
- Millet B, Bayle FJ, Olie JP. Prospects for anxiolytic therapy: a reflection from different viewpoints. Drug Discov Today 1998;3(10):471-9
- Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;329(19):1398-405
- Dement W. Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the multiple sleep latency test. J Clin Psychiatry 1991;52(Suppl):31-7
- Ebert B WK, Deacon S. Treating insomnia: current and investigational pharmacological approaches. Pharmacol Ther 2006;112(3):612-29
- Kallin K, Gustafson Y, Sandman PO, Karlsson S. Drugs and falls in older people in geriatric care settings. Aging Clin Exp Res 2004;16(4):270-6
- Takkouche B, Montes-Martinez A, Gill SS, Etminan M. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf 2007;30(2):171-84
- Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999;47(1):30-9
- Souchet E, Lapeyre-Mestre M, Montastruc JL. Drug related falls: a study in the french pharmacovigilance database. Pharmacoepidemiol Drug Saf 2005;14(1):11-16
- Wagner AK, Zhang F, Soumerai SB, Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med 2004;164(14):1567-72
- Pariente A DJ, Benichou J, Letenneur L, Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging 2008;25(1):61-70
- Greenblatt DJ, Harmatz JS, Shapiro L, Sensitivity to triazolam in the elderly. The New England Journal of Medicine 1991;324(24):1691-8
- Greenblatt DJ, Harmatz JS, von Moltke LL, Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome p450 3a substrate. Clin Pharmacol Ther 2004;76(5):467-79
- Potvin O, Hudon C, Forget H, Prevalence of psychiatric disorders in community-dwelling older men and women with cognitive impairment no dementia: results from the esa study. Aging Ment Health 2012;16(2):218-27
- Wu C-S, Wang CC, Chang I-S, Lin K-M. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. 2009;17:614-20
- Lagnaoui R, Begaud B, Moore N, Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol 2002;55(3):314-18
- Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open 2012;2(1):e000850
- World health organisation - assessment of zopiclone. Available from: http://www.who.int/medicines/areas/quality_safety/4.6ZopicloneCritReview.pdf [Accessed 2012]
- Scharf MB, Mayleben DW, Kaffeman M, Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 1991;52(2):77-83
- Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Primary Care Companion J Clin Psychiatry 1999;1(4):114-20
- Summary of product characteristics (SPC): Zimovane, zimovane ls. ABPI electronic medicine compendium 2007. Available from: http://www.medicines.org.uk/EMC/medicine/1675/SPC/Zimovane+7.5mg+%26+Zimovane+LS+3.75mg+film-coated+tablets [Accssessed 2012]
- Summary of product characteristics (SPC): Stilnoct 5mg, stilnoct 10mg. ABPI electronic medicine compendium 2007. Available from: http://www.medicines.org.uk/emc/history/6992/SPC/Stilnoct+5mg,+Stilnoct+10mg [Accessed 2012]
- EMEA European public assessment reports for sonata (zaleplon) 2007. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000227/human_med_001058.jsp&mid=WC0b01ac058001d124&murl=menus/medicines/medicines.jsp&jsenabled=true [Accessed 2012]
- Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry 2006;18(1):49-56
- FDA Lunesta prescribing information. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [Accessed 2012]
- FDA Ambien cr prescribing information. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [Accessed 2012]
- Dockhorn RJ, Dockhorn DW. Zolpidem in the treatment of short-term insomnia: a randomized, double-blind, placebo-controlled clinical trial. Clin Neuropharmacol 1996;19(4):333-40
- Scharf MB, Roth T, Vogel G, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55(5):192-9
- Krystal AD, Erman M, Zammit GK, Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008;31(1):79-90
- Moen MD, Plosker GL. Zolpidem extended-release. CNS Drugs 2006;20(5):419-26; discussion 427-418
- Roth T, Soubrane C, Titeux L, Walsh JK. Efficacy and safety of zolpidem-mr: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006;7(5):397-406
- Forrester MB. Immediate- and controlled-release zolpidem ingestions reported to texas poison centers. Hum Exp Toxicol 2009;28(8):505-9
- Allain H, Delahaye C, Le Coz F, Postmarketing surveillance of zopiclone in insomnia: analysis of 20,513 cases. Sleep 1991;14(5):408-13
- Walsh JK, Krystal AD, Amato DA, Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007;30(8):959-68
- Krystal AD, Walsh JK, Laska E, Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26(7):793-9
- Roth T, Walsh JK, Krystal A, An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005;6(6):487-95
- Ancoli-Israel S, Krystal AD, McCall WV, A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep 2010;33(2):225-34
- Brunner D, Dijk D-J, Munch M, Borbely A. Effect of zolpidem on sleep and sleep eeg spectra in healthy young men. Psychopharmacology 1991;104:1-5
- Trachsel L, Dijk DJ, Brunner DP, Effect of zopiclone and midazolam on sleep and eeg spectra in a phase-advanced sleep schedule. Neuropsychopharmacology 1990;3(1):11-18
- Borbely A. Processes underlying sleep regulation. Horm Res 1998;49:114-17
- Richardson GS, Roth T. Future directions in the management of insomnia. J Clin Psychiatry 2001;62(Suppl 10):39-45
- Hajak G, Muller WE, Wittchen HU, Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003;98(10):1371-8
- Soyka M, Bottlender R, Moller HJ. Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry 2000;33(4):138-41
- Victorri-Vigneau C, Dailly E, Veyrac G, Jolliet P. Evidence of zolpidem abuse and dependence: results of the French centre for evaluation and information on pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 2007;64(2):198-209
- Cimolai N. Zopiclone: is it a pharmacologic agent for abuse? Can Fam Physician 2007;53(12):2124-9
- Lovett B, Watts D, Grossman M. Prolonged coma after eszopiclone overdose. Am J Emerg Med 2007;25(6):735-6
- Zammit GK, McNabb LJ, Caron J, Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20(12):1979-91
- Zammit G. Comparative tolerability of newer agents for insomnia. Drug Saf 2009;32(9):735-48
- Leufkens TR, Lund JS, Vermeeren A. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J Sleep Res 2009;18(4):387-96
- Paul MA, Gray G, Kenny G, Pigeau RA. Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med 2003;74(12):1263-70
- Barbone F, McMahon AD, Davey PG, Association of road-traffic accidents with benzodiazepine use. Lancet 1998;352(9137):1331-6
- Gustavsen I, Bramness JG, Skurtveit S, Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med 2008;9(8):818-22
- Yang YH, Lai JN, Lee CH, Increased risk of hospitalization related to motor vehicle accidents among people taking zolpidem: a case-crossover study. J Epidemiol 2011;21(1):37-43
- Verster JC, Volkerts ER, Olivier B, Zolpidem and traffic safety - the importance of treatment compliance. Curr Drug Saf 2007;2(3):220-6
- Wang PS, Bohn RL, Glynn RJ, Zolpidem use and hip fractures in older people. J Am Geriatr Soc 2001;49(12):1685-90
- McCall VW. Sleep in the elderly: burden, diagnosis, and treatment. Prim Care Companion J Clin Psychiatry 2004;6(1):9-20
- Finkle WD, Der JS, Greenland S, Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults. J Am Geriatr Soc 2011;59(10):1883-90
- Rhalimi M, Helou R, Jaecker P. Medication use and increased risk of falls in hospitalized elderly patients: a retrospective, case-control study. Drugs Aging 2009;26(10):847-52
- NPS: National prescribing service (australia) position statement -zolpidem and sleep-related behaviours. Available from: http://wwwnpsorgau/data/assets/pdf_file/0011/59888/Zolpidem_position_statement_To_printpdf [Accessed 2012]
- Chiang A, Krystal A. Report of two cases where sleep related eating behavior occurred with the extended-release formulation but not the immediate-release formulation of a sedative-hypnotic agent. J Clin Sleep Med 2008;4(2):155-6
- Cohn MA. Effects of zolpidem, codeine phosphate and placebo on respiration. A double-blind, crossover study in volunteers. Drug Saf 1993;9(4):312-19
- Mintzer MZ, Griffiths RR. Selective effects of zolpidem on human memory functions. J Psychopharmacol 1999;13(1):18-31
- Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines: a review. Pharmacol Biochem Behav 1998;61(3):253-69
- Rush CR, Armstrong DL, Ali JA, Pazzaglia PJ. Benzodiazepine-receptor ligands in humans: acute performance-impairing, subject related and observer-rated effects. J Clin Psychopharmacol 1998;18(2):154-65
- Morgan PT, Kehne JH, Sprenger KJ, Malison RT. Retrograde effects of triazolam and zolpidem on sleep-dependent motor learning in humans. J Sleep Res 2010;19(1 Pt 2):157-64
- Chavant F. Favreliere S,Lafay-Chebassier C, et al.Memory disorders associated with drugs consumption: updating through a case/ noncase study in the french pharmacovigilance database. Br J Clin Pharmacol 2011;72(6):898-904
- Mort JR, Aparasu RR. Prescribing of psychotropics in the elderly: why is it so often inappropriate? CNS Drugs 2002;16(2):99-109
- Lader MH. Abuse potential, tolerance and dependence on chronic anxiolytic treatment. In: Mendlewicz J, Racagni G, editors. Abuse and dependence of anxiolytics. Karger; Basel: 1992. p. 46-54
- Hohagen F, Rink K, Kappler C, Prevalence and treatment of insomnia in general practice. Eur Arch Psychiatry Clin Neurosci 1993;242:329-36
- Rajaratnam SM, Polymeropoulos MH, Fisher DM, Melatonin agonist tasimelteon (vec-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009;373(9662):482-91
- Yalkinoglu O, Zisapel N, Nir T, Phase-i study of the safety, tolerability, pharmacokinetics and sleep promotingactivity of neu-p11, a novel putative insomnia drug in healthy humans. Sleep 33:2010(Suppl):A220
- Brzezinski A. Melatonin in humans. The New England Journal of Medicine 1997;336(3):186-95
- Skene DJ, Arendt J. Circadian rhythm sleep disorders in the blind and their treatment with melatonin. Sleep Med 2007;8(6):651-5
- Cajochen C, Drauchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 2003;15:432-7
- Gorfine T, Assaf Y, Goshen-Gottstein Y, Sleep-anticipating effects of melatonin in the human brain. Neuroimage 2006;31(1):410-18
- Gorfine T, Zisapel N.. Late evening brain activation patterns and their relation to the internal biological time, melatonin, and homeostatic sleep debt. Hum Brain Mapp 2009;30(2):541-52
- Altena E, Vrenken H, Van Der Werf YD, Reduced orbitofrontal and parietal gray matter in chronic insomnia: a voxel-based morphometric study. Biol Psychiatry 2010;67(2):182-5
- Fukunaga M, Horovitz SG, van Gelderen P, Large-amplitude, spatially correlated fluctuations in bold fmri signals during extended rest and early sleep stages. Magn Reson Imaging 2006;24(8):979-92
- Horovitz SG, Fukunaga M, de Zwart JA, Low frequency bold fluctuations during resting wakefulness and light sleep: a simultaneous eeg-fmri study. Hum Brain Mapp 2008;29(6):671-82
- Rajaratnam SMW, Middleton B, Stone BM, Melatonin advances the circadian timing of eeg sleep and directly facilitates sleep without altering its duration in extended sleep opportunities. J Physiol 2004;561(Pt 1):1339-51
- Zisapel N. Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. CNS Drugs 2001;15(4):311-28
- Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag 2011;7:577-84
- Wade A, Zisapel N, Lemoine P. Prolonged-release melatonin for the treatment of insomnia: targeting quality of sleep and morning alertness. Aging Health 2008;1:11-21
- Wade AG, Ford I, Crawford G, Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010;8(1):51
- Mayer G, Wang-Weigand S, Roth-Schechter B, Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009;32(3):351-60
- Pandi-Perumal SR, Trakht I, Srinivasan V, Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008;85(3):335-53
- Brzezinski A. Melatonin in humans. N Engl J Med 1997;336(3):186-95
- Nave R, Peled R, Lavie P. Melatonin improves evening napping. Eur J Pharmacol 1995;275:213-16
- Zhdanova IV, Wurtman R. Efficacy of melatonin as a sleep-promoting agent. J Biol Rhythms 1997;12(6):644-50
- Krauchi K, Cajochen C, Werth E, Wirz-Justice A. Functional link between distal vasodilation and sleep-onset latency? Am J Physiol Regul Intergr Comp Physiol 2000;278:R741-8
- Iguichi H, Kato K-I, Ibayashi H. Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis. J Clin Endocrinol Metab 1982;54(5):1025-7
- Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity mt1 and mt2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 2006;46(2):140-8
- Pandi-Perumal SR, Srinivasan V, Spence DW, Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther 2009;26(6):613-26
- FDA Ramelteon: Clinical review. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [Accessed 2012]
- Kohsaka M, Kanemura T, Taniguchi M, Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in japanese patients with chronic primary insomnia. Expert Rev Neurother 2011;11(10):1389-97
- Miyamoto M. Pharmacology of ramelteon, a selective mt1/mt2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther 2009;15(1):32-51
- Uchiyama M, Hamamura M, Kuwano T, Long-term safety and efficacy of ramelteon in japanese patients with chronic insomnia. Sleep Med 2011;12(2):127-33
- Richardson G, Wang-Weigand S. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. Hum Psychopharmacol 2009;24(2):103-11
- Richardson G, Wang-Weigand S. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. Hum Psychopharmacol 2009;24(2):103-11
- Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005;66(Suppl 9):31-41
- Zammit G, Erman M, Wang-Weigand S, Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;3(5):495-504
- Mets MA, Volkerts ER, Olivier B, Verster JC. Effect of hypnotic drugs on body balance and standing steadiness. Sleep Med Rev 2010;14(4):259-67
- Mets MA, de Vries JM, de Senerpont Domis LM, Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. Sleep 2011;34(10):1327-34
- Zammit G, Wang-Weigand S, Rosenthal M, Peng X. Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia. J Clin Sleep Med 2009;5(1):34-40
- Erman M, Seiden D, Zammit G, An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7(1):17-24
- Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007;23(5):1005-14
- Yeleswaram K, McLaughlin LG, Knipe JO, Schabdach D. Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. J Pineal Res 1997;22(1):45-51
- Arendt J, Bojkowski C, Franey C, Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine:abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 1985;60(6):1166-73
- Waldhauser F, Waldhauser M, Lieberman HR, Bioavailability of oral melatonin in humans. Neuroendocrinology 1984;39(4):307-13
- EMA: Circadin: European medicines agency public assessment reports for circadin. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/circadin/circadin.htm [Accessed 2012]
- EMA: Circadin: Product Information (SPC). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000695/WC500026811.pdf [Accessed 2012]
- Haimov I, Laudon M, Zisapel N, Sleep disorders and melatonin rhythms in elderly people. BMJ 1994;309:167
- Kennaway DJ, Lushington K, Dawson D, Urinary 6-sulfatoxymelatonin excretion and aging: new results and a critical review of the literature. J Pineal Res 1999;27:210-20
- Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004;116(2):91-5
- Czeisler CA, Duffy JF, Shanahan TL, Stability, precision, and near-24-hour period of the human circadian pacemaker. Science 1999;284(5423):2177-81
- Hofman MA, Swaab DF. Alterations in circadian rhythmicity of the vasopressin-producing neurons of the human suprachiasmatic nucleus (scn) with aging. Brain Res 1994;651(1-2):134-42
- Buysse D, Reynolds C III, Monk T, The pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213
- Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 2009;24(5):239-49
- Arbon E, Knoriwska M, Dijk D. Comparing the effects of prolonged release melatonin, temazepam and zolpidem on eeg power spectra during nocturnal sleep in healthy middle aged men and women. J Sleep Res 2010;19(Suppl 2):198
- Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007;16:372-80
- Wade AG, Ford I, Crawford G, Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007;23(10):2597-605
- Wade AG, Ford I, Crawford G, Prolonged release melatonin in the treatment of primary insomnia - evaluation of the age cut-off for short and long-term response. CMRO 2011;27(1):87-98
- Garfinkel D, Zorin M, Wainstein J, Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes 2011;4:307-13
- Lemoine P, Wade A, Katz A, Efficacy and safety of prolonged release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials. Integr Blood Press Control 2012;5:9-17
- Lemoine P, Garfinkel D, Laudon M, Prolonged release melatonin for insomnia - an open label long term study of efficacy, safety and withdrawal symptoms. Ther Clin Risk Manag 2011;7:301-11
- Otmani S, Demazieres A, Staner C, Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol 2008;23(8):693-705
- Paul MA, Brown G, Buguet A, Melatonin and zopiclone as pharmacologic aids to facilitate crew rest. Aviat Space Environ Med 2001;72(11):974-84
- Paul MA, Gray G, Sardana TM, Pigeau RA. Melatonin and zopiclone as facilitators of early circadian sleep in operational air transport crews. Aviation Space Environ Med 2004;75(5):439-43
- Paul MA, Gray G, Maclellan M, Pigeau RA. Sleep-inducing pharmaceuticals: a comparison of melatonin, zaleplon, zopiclone, and temazepam. Aviation Space Environ Med 2004;75(6):512-19
- Otmani EA. Effects of prolonged-release melatonin and zolpidem on postural stability in older adults. Human Psychopharmacology. Clin Exp 2012; Epub ahead of print
- Lin JS, Sakai K, Vanni-Mercier G, Involvement of histaminergic neurons in arousal mechanisms demonstrated with h3-receptor ligands in the cat. Brain Res 1990;523(2):325-30
- Roth T, Rogowski R, Hull S, Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007;30(11):1555-61
- Scharf M, Rogowski R, Hull S, Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008;69(10):1557-64
- Krystal AD, Lankford A, Durrence HH, Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 2011;34(10):1433-42
- Lankford A, Rogowski R, Essink B, Efficacy and safety of doxepin 6mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med 2012;13(2):133-8
- Krystal AD, Durrence HH, Scharf M, Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2010;33(11):1553-61
- FDA Silenor approval and label history. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [Accessed 2012]
- Alter P, Tontsch D, Grimm W. Doxepin-induced torsades de pointes tachycardia. Ann Intern Med 2001;135:384-5
- FDA Silenor approval and label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022036lbl.pdf [Accessed 2012]
- Nau SD LK. Insomnia: Causes and treatments. In: Carney PR BR, Geyer JD, editors. Clinical sleep disorders. Lippincott Williams & Wilkins; Philadelphia: 2005. p. 157-90
- Zhang D, Tashiro M, Shibuya K, Next-day residual sedative effect after nighttime administration of an over-the-counter antihistamine sleep aid, diphenhydramine, measured by positron emission tomography. J Clin Psychopharmacol 2010;30(6):694-701
- Shields K, Lesher B. Treatments for insomnia. Pharmacist's Lett Prescriber's Lett 2005;21:1-5
- Wiegand MH. Antidepressants for the treatment of insomnia : a suitable approach? Drugs 2008;68(17):2411-17
- Walsh J, Erman M, Erwin C, Subjective hypnotic effect of trazodone and zolpidem in dsm-iii-r primary insomnia. Hum Psychopharmacol 1998;13(3):191-8
- Riemann D, Voderholzer U, Cohrs S, Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 2002;35(5):165-74
- Winokur A, DeMartinis NA III, McNally DP, Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. The Journal of clinical psychiatry 2003;64(10):1224-9
- Radhakishun FS, van den Bos J, van der Heijden BC, Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol 2000;20(5):531-7
- Kennedy SH, Eisfeld BS. Agomelatine and its therapeutic potential in the depressed patient. Neuropsychiatr Dis Treat 2007;3(4):423-8
- EMA: Guideline on medicinal products for the treatment of insomnia. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/02/WC500102351.pdf [Accessed 2012]
- Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev 2011;15(4):269-81
- Teegarden BR, Al Shamma H, Xiong Y. 5-ht(2a) inverse-agonists for the treatment of insomnia. Curr Top Med Chem 2008;8(11):969-76
- Demyttenaere K. Agomelatine: a narrative review. Eur Neuropsychopharmacol 2011;21(Suppl 4):S703-9
- Sakurai T, Amemiya A, Ishii M, Orexins and orexin receptors: a family of hypothalamic neuropeptides and g protein-coupled receptors that regulate feeding behavior. Cell 1998;92(4):573-85
- de Lecea L, Kilduff TS, Peyron C, The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95(1):322-7
- Peyron C, Tighe DK, van den Pol AN, Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18(23):9996-10015
- Zeitzer JM, Buckmaster CL, Parker KJ, Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 2003;23(8):3555-60
- Lin L, Faraco J, Li R, The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98(3):365-76
- Chemelli RM, Willie JT, Sinton CM, Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98(4):437-51
- Selbach O, Haas HL. Hypocretins: the timing of sleep and waking. Chronobiol Int 2006;23(1-2):63-70
- Langmead CJ, Jerman JC, Brough SJ, Characterisation of the binding of [3h]-sb-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 2004;141(2):340-6
- Brisbare-Roch C, Dingemanse J, Koberstein R, Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007;13(2):150-5
- Hoever P, de Haas S, Winkler J, Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther 2010;87(5):593-600
- Herring WJ BK, Hutzelmann J, Snyder E, Efficacy and tolerability of the dual orexin receptor antagonist mk-4305 in patients with primary insomnia: randomized, controlled, adaptive crossover polysomnography study Sleep. 2010;33(Suppl):A199-0591
- Nct01097629 Available from: http://clinicaltrials.gov/ct2/show/NCT01097629?term=NCT01097629&rank=1 [Accessed 2012]
- Nct01097616 Available from: http://clinicaltrials.gov/ct2/show/NCT01097616?term=suvorexant&rank=1 [Accessed 2012]
- Nct01021813 Available from: http://clinicaltrials.gov/ct2/show/NCT01021813?term=NCT01021813&rank=1 [Accessed 2012]
- FDA: Es-zopiclone. Clinical review. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=ESZOPICLONE [Accessed 2012]
- FDA: Zolpidem: Clinical review. Available from: http://www.fda.gov/cder/foi/nda/pre96/019908_S000_AmbienTOC.htm [Accessed 2012]
- EMA European public assessment reports for sonata (zaleplon) 2007. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000227/human_med_001058.jsp&mid=WC0b01ac058001d124 [Accessed 2012]